Boehringer to give Germany first blood of its BP franchise defence
This article was originally published in Scrip
Executive Summary
Boehringer Ingelheim is launching its combination antihypertensive, Twynsta (telmisartan plus amlodipine), in Germany on 21 October, making it the first EU launch market, after the company got the OK from the European Commission on 12 October. This comes after the EU CHMP gave the product the greenlight in July (scripintelligence.com 23 July 2010). The product was approved in the US in October 2009 and in Japan in July 2010.